These results strongly suggest that the novel mAbs could have a therapeutic potential similar to clinically effective anti-CTLA-4 mAbs, reported to cause tumor rejection by mechanisms that are dependent on the host Fc receptor [41]. The gene discussed is CTLA4; the disease is neoplasm.